Clinical trials: Moderately Obese
Obesity
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study
- Trial name
- NCT07000955
- Testing
- Tirzepatide, IBI362
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Sleep Apnea, Obstructive
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index…
- Conditions
- Sleep Apnea, Obstructive, Obesity
- Trial name
- NCT06931028
- Testing
- IBI362
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity
The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)
The objective for this clinical study is to provide FDA with clinical evidence regarding the effectiveness and safety of the AGBS + moderate intensity lifestyle modification therapy program, indwell time of the AGBS inside the…
- Trial name
- AUDACITY (NCT05368259)
- Testing
- AGBS
- Where
- 17 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Allurion Technologies
Hypertension, Diabetes Mellitus, Type 2
SMOOTH - Blood Pressure Control in Diabetic/Obese Patients
The primary objective of this study is to demonstrate that telmisartan 80 mg combined with hydrochlorothiazide 12.5 mg (T80/H12.5) is at least as effective and possibly superior to valsartan 160 mg combined with…
- Trial name
- NCT00239538
- Testing
- telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
- Where
- 102 sites in United States, Argentina and 6 more
- Volunteers
- 840 people
- Sponsor
- Boehringer Ingelheim
Overweight and Obesity
Efficacy and Safety of Glucosanol™ in Body Weight Reduction
It was proven in a previous clinical study that Glucosanol™ is effective and safe in reducing weight in the overweight and obese.
- Trial name
- NCT02930668
- Testing
- Glucosanol 350mg, Glucosanol 500mg
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity; Excess Calories, Overweight and Obesity
Efficacy and Safety of Litramine in 1 Year Weight Loss Study
To evaluate the efficacy of Litramine in reducing body weight in the context of an energy-restricted diet in overweight and moderately obese subjects
- Conditions
- Obesity; Excess Calories, Overweight and Obesity, Weight Loss
- Trial name
- NCT03227276
- Testing
- Litramine
- Where
- Germany
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Overweight, Obesity
DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
The main study objective is to evaluate the efficacy of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects, in the context of an energy restricted diet.
- Trial name
- NCT04086797
- Testing
- IQP-AE-103
- Where
- Germany
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Perrigo CSCI
Obesity & Overweight
A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of VCT220 (other name: CX11) in subjects with moderate renal impairment compared with age-, sex-, and body mass index (BMI)-matched…
- Trial name
- NCT07347808
- Testing
- VCT220
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Adverse Drug Event, Side Effects of Drugs
Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure
The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.
- Trial name
- NCT03112083
- Testing
- Nutritional counseling A, Nutritional counselling B
- Where
- Finland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Olympic Seafood AS
Overweight, Obesity
Benefit and Tolerability of IQP-AE-103 in Weight Loss
This study is to evaluate the benefit and tolerability of two dosages of IQP-AE-103 (990mg and 1980mg daily) in reducing body weight in overweight and moderately obese subjects
- Trial name
- NCT03058367
- Testing
- IQP-AE-103 (330mg), IQP-AE-103 (165mg)
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity and Overweight, Moderately Obese
EXploratory Study on Postprandial Energy Metabolism
This exploratory, double-blinded clinical trial on 66 randomized adults aged 50 to 70 years with moderate overweight or obesity but considered metabolically healthy will consist of comparing metabolic and microbiota parameters…
- Trial name
- EXPEM (NCT06786052)
- Testing
- Probiotic
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Overweight and Obesity, Body Weight Changes
Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management
PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120).
- Conditions
- Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise
- Trial name
- PHAEOSOL-ONE (NCT04761406)
- Testing
- Phaeosol group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Microphyt
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity, Binge-Eating Disorder
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity
The purpose of this study is to evaluate the safety and effectiveness of topiramate compared to placebo in reducing the number of binge days in patients with moderate to severe binge-eating disorder associated with obesity.
- Trial name
- NCT00210808
- Testing
- topiramate
- Volunteers
- 407 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight, Obesity
Benefit and Tolerability of IQP-LU-104 in Weight Loss
This study is to evaluate the benefit and tolerability of two dosages of IQP-LU-104 (5120mg and 2560mg daily) in reducing body weight in overweight and moderately obese subjects
- Trial name
- NCT03888911
- Testing
- High dose IQP-LU-104 (5120mg), Low dose IQP-LU-104 (2560mg)
- Where
- Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.
- Trial name
- NCT06994650
- Testing
- HRS9531
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight, Obesity
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received…
- Conditions
- Overweight, Obesity, Hypertensive
- Trial name
- NCT07469800
- Testing
- IBI362
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers
This study is the First Time in Human Study for GSK2256294 and will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of GSK2256294 administered to healthy male…
- Trial name
- NCT01762774
- Testing
- GSK2256294
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obstructive Sleep Apnea (OSA)
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea…
- Trial name
- NCT07493057
- Testing
- GZR18 injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Obstructive Sleep Apnea, Obesity
UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
The objective of this clinical trial is to evaluate the efficacy of investigational drug UBT251 in the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, as well as to assess its safety.
- Trial name
- UNISHAPE-OSA-1 (NCT07767942)
- Testing
- UBT251
- Volunteers
- 150 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.